Kura Oncology (KURA) added ~5% in the premarket on Friday after releasing positive data from a Phase 1 trial for its next-gen farnesyl transferase inhibitor, darlifarnib (KO-2806), in patients with ...

Switching to a second-line Janus kinase (JAK) inhibitor resulted in steroid-free clinical remission in about half of the patients with active ulcerative colitis (UC) after induction; compared with ...

Reduction of Metastatic Spread: The addition of INB03 significantly reduced the incidence of metastases to brain, lung, and liver (quantified by ex-vivo IVIS luminescence imaging). Notably, it further ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute ...

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial ...

Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in ...

Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of ...